Consolidated Statements of Income and Comprehensive Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands		3 Months Ended
		Mar. 31, 2020	Mar. 31, 2019
Revenues	[1]	$ 25,814	$ 18,882
Cost of products sold		18,480	13,798
Gross profit		7,334	5,084
Operating expenses:
Research and development		1,548	1,036
Selling, general and administrative		4,301	3,500
Total operating expenses		5,849	4,536
Operating income		1,485	548
Other (expense) income:
Interest and financing expense		(174)	(5)
Miscellaneous income (expense)		82	(53)
Total other expense		(92)	(58)
Income before income taxes		1,393	490
Income tax provision		319	41
Net income		1,074	449
Net income attributable to non-controlling interest		(15)	(24)
Net income attributable to Ultralife Corporation		1,059	425
Other comprehensive (loss) gain:
Foreign currency translation adjustments		(807)	435
Comprehensive income attributable to Ultralife Corporation		$ 252	$ 860
Net income per share attributable to Ultralife common shareholders – basic (in dollars per share)		$ 0.07	$ 0.03
Net income per share attributable to Ultralife common shareholders – diluted (in dollars per share)		$ 0.07	$ 0.03
Weighted average shares outstanding – basic (in shares)		15,875	15,740
Potential common shares (in shares)		212	485
Weighted average shares outstanding - diluted (in shares)		16,087	16,225

[1] Sales classified to U.S. include shipments to U.S.-based prime contractors which in some cases may serve non-U.S. projects